Session Abstract – PMWC 2020 Silicon Valley


Artificial intelligence holds the promise to revolutionize health care and directly impact the clinical trials process via expediting the recruitment of eligible clinical trial patients. The systems currently developed with the use of AI/ML enable higher patient enrollment rates and better trial assignment, contribute to reducing the cost of recruitment via additional/more efficient medical tests, and facilitate analysis and integration of operational data from historical cases. This session focuses on various applications of AI in clinical trial design and patient selection.

 Session Chair Profile

Strategic Global Client Lead, Google Cloud

Biography
At Google Cloud, Shweta is the strategic client lead responsible for Healthcare and Life Sciences. Shweta has quickly risen through the ranks as a well-known innovator, game-changer, and relationship ambassador. With 18+ years’ experience in clinical research, Healthcare and Bio Tech, she has proven time and time again how valuable relationships can be by enabling dozens of start-up firms with access to capital from Federal grants and VC firms alike. She brings an eye for detail, winning contract negotiations, and financial insight to support her commercial partnership strategy expertise. A position was created just for her, after excelling in a Commercial Partnering and Strategy role at Genentech. She has been the recipient of multiple awards at Genentech, including two “Innovation Awards,” “MVP Award,” and more. Shweta brings an impressive network of established healthcare system relationships across Digital Health & Technology, Investor, Pharmaceutical, Medical Device, and Hospital Systems Industries. She is passionate about keeping current with trends in medical devices, data, wearables, IoT, EHR, and machine learning. Since joining Google, Shweta develops and manages a variety of customer and partnership relationships while identifying new opportunities.


 Speaker Profile

Ph.D., Co-Founder and CEO, DNAstack

Biography
Dr. Marc Fiume is an entrepreneur, researcher, and thought-leader in genomics and clinical data sharing. Marc is the Co-founder and CEO of DNAstack, a Toronto-based software company that technologies that accelerate collaborative biomedical research, supported by major cloud providers and academic and clinical research partners around the world. Marc co-chairs the Discovery Work Stream for the Global Alliance for Genomics & Health, which develops open and interoperable standards to enable real-time search engines across globally federated biomedical data. His team develops the Beacon Network, the world’s largest search engine for public sharing of genomic mutations, which has facilitated millions of searches and has led to disease-gene discoveries and clinical translation.


 Speaker Profile

Global Head, Digital Development, Global Clinical Operations, Boehringer Ingelheim Pharmaceuticals

Biography
Mohammed (Mo) Ali is currently the global lead for digital development at Boehringer Ingelheim Pharmaceuticals. Prior to this role, he served as a Director within the R&D Operations and Innovations group at J&J Pharmaceuticals and also within the digital development group and Strategic Program Office at Novartis, responsible for several "E" initiatives within Digital Health. These programs aim to serve the needs of patients by creating a digital footprint and platform which would assist in the overall tracking, delivery, and enrichment of their experience.


 Speaker Profile

M.D., Ph.D., VP Scientific & Medical Affairs, Molecular Health GmbH

Biography
Dr Armin Schneider has 20 years track record in leading roles in Biotech drug discovery and development and MD PhD from the University of Heidelberg, Germany. At Molecular Health, Armin pioneers the utilization of the company’s technology, Dataome® – a mighty clinical-molecular knowledge base of drugs, diseases and outcomes into machine learning applications and predictive algorithms to predict drug outcomes and R&D efficiency. He has authored over 150 publications and owns numerous patent families and has a strong background in neurology, pharmacology, molecular biology, and statistics, and specific interest in questions of applying advanced statistical methodology to drug development.


 Speaker Profile

Ph.D., Chief Scientist, Cancer Commons

Biography
Emma Shtivelman is a molecular and cell biologist with extensive experience in cancer biology. Emma received her PhD from the Weizmann Institute of Science, where she identified the fused transcript between BCR and ABL in chronic myeloid leukemia (CML), the first demonstration of an oncogenic gene product derived from a chromosomal translocation. As a postdoctoral fellow at the University of California, San Francisco (UCSF), she characterized the molecular consequences of chromosomal alterations in Burkitt’s lymphoma, and studied the pathogenesis of neuroblastoma. She worked at Systemix, establishing a novel SCID-hu metastasis model to enable the in vivo analysis of human tumor metastasis. She continued her research in signal transduction pathways in cancer and its metastatic progression at the UCSF Cancer Center and biotech before joining Cancer Commons. As a Chief Scientist, she works directly with cancer patients, identifying the most promising clinical trials for each and every patient, and helping them find the best experts and treatments.